AIM ImmunoTech Inc. is set to attend the Marie Sklodowska-Curie Symposia on Cancer Research & Care in Warsaw, Poland, in September. At the event, AIM CEO Thomas K. Equels plans to work on establishing government- and industry-funded clinical partnerships and potential licensing agreements in Europe, focusing on Poland.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.